195 related articles for article (PubMed ID: 38570507)
21. Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study.
Najjar YG; Navrazhina K; Ding F; Bhatia R; Tsai K; Abbate K; Durden B; Eroglu Z; Bhatia S; Park S; Chowdhary A; Chandra S; Kennedy J; Puzanov I; Ernstoff M; Vachhani P; Drabick J; Singh A; Xu T; Yang J; Carvajal R; Manson D; Kirkwood JM; Cohen J; Sullivan R; Johnson D; Funchain P; Shoushtari A
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581057
[TBL] [Abstract][Full Text] [Related]
22. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
23. Is tebentafusp superior to combined immune checkpoint blockade and other systemic treatments in metastatic uveal melanoma? A comparative efficacy analysis with population adjustment.
Petzold A; Steeb T; Wessely A; Koch EAT; Vera J; Berking C; Heppt MV
Cancer Treat Rev; 2023 Apr; 115():102543. PubMed ID: 36931146
[TBL] [Abstract][Full Text] [Related]
24. The efficacy of immune checkpoint inhibitors in advanced hepatocellular carcinoma: a meta-analysis based on 40 cohorts incorporating 3697 individuals.
Wang R; Lin N; Mao B; Wu Q
J Cancer Res Clin Oncol; 2022 May; 148(5):1195-1210. PubMed ID: 34297207
[TBL] [Abstract][Full Text] [Related]
25. Triple combination of HAIC-FO plus tyrosine kinase inhibitors and immune checkpoint inhibitors for advanced hepatocellular carcinoma: A systematic review and meta-analysis.
Tan Z; Zhang J; Xu L; Wang H; Mao X; Zou R; Wang Q; Han Z; Di Z; Wu D
PLoS One; 2023; 18(10):e0290644. PubMed ID: 37844117
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of radiotherapy combined with immune checkpoint inhibitors in patients with melanoma: a systemic review and meta-analysis.
Yin G; Guo W; Huang Z; Chen X
Melanoma Res; 2022 Apr; 32(2):71-78. PubMed ID: 35254329
[TBL] [Abstract][Full Text] [Related]
27. Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis.
Goldinger SM; Buder-Bakhaya K; Lo SN; Forschner A; McKean M; Zimmer L; Khoo C; Dummer R; Eroglu Z; Buchbinder EI; Ascierto PA; Gutzmer R; Rozeman EA; Hoeller C; Johnson DB; Gesierich A; Kölblinger P; Bennannoune N; Cohen JV; Kähler KC; Wilson MA; Cebon J; Atkinson V; Smith JL; Michielin O; Long GV; Hassel JC; Weide B; Haydu LE; Schadendorf D; McArthur G; Ott PA; Blank C; Robert C; Sullivan R; Hauschild A; Carlino MS; Garbe C; Davies MA; Menzies AM
Eur J Cancer; 2022 Feb; 162():22-33. PubMed ID: 34952480
[TBL] [Abstract][Full Text] [Related]
28. Predictive impact of sarcopenia in solid cancers treated with immune checkpoint inhibitors: a meta-analysis.
Takenaka Y; Oya R; Takemoto N; Inohara H
J Cachexia Sarcopenia Muscle; 2021 Oct; 12(5):1122-1135. PubMed ID: 34337889
[TBL] [Abstract][Full Text] [Related]
29. New Zealand national retrospective cohort study of survival outcomes of patients with metastatic melanoma receiving immune-checkpoint inhibitors.
Ab Rahman AS; Strother RM; Paddison J
Asia Pac J Clin Oncol; 2023 Feb; 19(1):179-186. PubMed ID: 35686690
[TBL] [Abstract][Full Text] [Related]
30. MBD4 deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patients.
Saint-Ghislain M; Derrien AC; Geoffrois L; Gastaud L; Lesimple T; Negrier S; Penel N; Kurtz JE; Le Corre Y; Dutriaux C; Gardrat S; Barnhill R; Matet A; Cassoux N; Houy A; Ramtohul T; Servois V; Mariani P; Piperno-Neumann S; Stern MH; Rodrigues M
Eur J Cancer; 2022 Sep; 173():105-112. PubMed ID: 35863105
[TBL] [Abstract][Full Text] [Related]
31. Immune checkpoint inhibitors in advanced cutaneous melanoma: a systematic review and meta-analysis of efficacy and review of characteristics.
Mahdiabadi S; Momtazmanesh S; Karimi A; Rezaei N
Expert Rev Anticancer Ther; 2023; 23(12):1281-1293. PubMed ID: 37908134
[TBL] [Abstract][Full Text] [Related]
32. Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis.
Saerens M; Brusselaers N; Rottey S; Decruyenaere A; Creytens D; Lapeire L
Eur J Cancer; 2021 Jul; 152():165-182. PubMed ID: 34107450
[TBL] [Abstract][Full Text] [Related]
33. Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma.
Sun M; Ji H; Xu N; Jiang P; Qu T; Li Y
BMC Cancer; 2022 Jul; 22(1):762. PubMed ID: 35831785
[TBL] [Abstract][Full Text] [Related]
34. Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11).
Kim H; Kim DW; Kim M; Lee Y; Ahn HK; Cho JH; Kim IH; Lee YG; Shin SH; Park SE; Jung J; Kang EJ; Ahn MJ
Cancer; 2022 Feb; 128(4):778-787. PubMed ID: 34705268
[TBL] [Abstract][Full Text] [Related]
35. Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: A systematic review and meta-analysis.
Boutros A; Bruzzone M; Tanda ET; Croce E; Arecco L; Cecchi F; Pronzato P; Ceppi M; Lambertini M; Spagnolo F
Eur J Cancer; 2021 Dec; 159():154-166. PubMed ID: 34753012
[TBL] [Abstract][Full Text] [Related]
36. Sex-related differences in serum biomarker levels predict the activity and efficacy of immune checkpoint inhibitors in advanced melanoma and non-small cell lung cancer patients.
Pasello G; Fabricio ASC; Del Bianco P; Salizzato V; Favaretto A; Piccin L; Zustovich F; Fabozzi A; De Rossi C; Pigozzo J; De Nuzzo M; Cappelletto E; Bonanno L; Palleschi D; De Salvo GL; Guarneri V; Gion M; Chiarion-Sileni V
J Transl Med; 2024 Mar; 22(1):242. PubMed ID: 38443899
[TBL] [Abstract][Full Text] [Related]
37. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.
Rose AAN; Armstrong SM; Hogg D; Butler MO; Saibil SD; Arteaga DP; Pimentel Muniz T; Kelly D; Ghazarian D; King I; Kamil ZS; Ross K; Spreafico A
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483342
[TBL] [Abstract][Full Text] [Related]
38. Outcome of immune checkpoint inhibitors in metastatic renal cell carcinoma across different treatment lines.
Resch I; Bruchbacher A; Franke J; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
ESMO Open; 2021 Aug; 6(4):100122. PubMed ID: 34217917
[TBL] [Abstract][Full Text] [Related]
39. Treatment-free survival after discontinuation of immune checkpoint inhibitors in metastatic renal cell carcinoma: a systematic review and meta-analysis.
Tzeng A; Tzeng TH; Ornstein MC
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599022
[TBL] [Abstract][Full Text] [Related]
40. Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma.
Klemen ND; Wang M; Rubinstein JC; Olino K; Clune J; Ariyan S; Cha C; Weiss SA; Kluger HM; Sznol M
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32209601
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
